CASI PHARMACEUTICALS INC (CASI)

KYG1933S1012 - Common Stock

3  0 (0%)

News Image
40 minutes ago - CASI Pharmaceuticals

CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2023 BUSINESS AND FINANCIAL RESULTS

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative...

News Image
23 days ago - CASI Pharmaceuticals

CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma In China

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company specializing in the development and commercialization of innovative...

News Image
a month ago - CASI Pharmaceuticals

CASI PHARMACEUTICALS ANNOUNCES FIRST DOSING OF FOLOTYN® IN CHINA

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company specializing in the development and commercialization of innovative...

News Image
4 months ago - CASI Pharmaceuticals

CASI PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2023 BUSINESS AND FINANCIAL UPDATES

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company focused on developing and commercializing innovative therapeutics and...

News Image
5 months ago - CASI Pharmaceuticals

CASI PHARMACEUTICALS ANNOUNCES MARKET APPROVAL OF CNCT19 BY CHINA NMPA

/PRNewswire/ -- CASI Pharmaceuticals Inc. (Nasdaq: CASI), a biopharmaceutical company focused on developing and commercializing innovative therapeutics and...

News Image
6 months ago - InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Pre-market stock movers are a hot topic on Wednesday morning and we're covering all of the latest news investors need to know about!

News Image
8 months ago - CASI Pharmaceuticals, Inc.

CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2023 BUSINESS AND FINANCIAL UPDATES

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company focused on developing and commercializing innovative therapeutics and...

News Image
8 months ago - CASI Pharmaceuticals, Inc.

Mundipharma International Corporation Limited, Mundipharma Medical Company, and Acrotech Biopharma Inc. Enter Agreement to Transfer License of FOLOTYN® (Pralatrexate) in China to CASI Pharmaceuticals

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company focused on developing and commercializing innovative therapeutics and...

News Image
11 months ago - CASI Pharmaceuticals, Inc.

CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2023 FINANCIAL RESULTS

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman Islands incorporated biopharmaceutical company focused on developing and commercializing...

News Image
a year ago - CASI Pharmaceuticals, Inc.

CASI Pharmaceuticals Files Annual Report on Form 20-F for Fiscal Year 2022

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ: CASI) ("CASI" or the "Company"), a biopharmaceutical company focused on developing and commercializing...

News Image
a year ago - CASI Pharmaceuticals, Inc.

CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2022 FINANCIAL RESULTS

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative...

News Image
a year ago - CASI Pharmaceuticals, Inc.

CASI PHARMACEUTICALS COMPLETES REDOMICILIATION MERGER

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ: CASI) ("CASI" or the "Company"), a biopharmaceutical company focused on developing and commercializing...

News Image
a year ago - CASI Pharmaceuticals, Inc.

CASI PHARMACEUTICALS AND CLEAVE THERAPEUTICS ANNOUNCE CLINICAL TRIAL APPLICATION APPROVAL FOR CB-5339 IN PATIENTS WITH MULTIPLE MYELOMA IN CHINA

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics...

News Image
a year ago - Seeking Alpha

CASI stock spikes as CAR-T therapy undergoes review in China for leukemia (NASDAQ:CASI)

CASI Pharmaceuticals (CASI) announced Thursday that China accepted the marketing application submitted by Juventas Cell Therapy, Ltd for CNCT19 in leukemia. Read the full story here.

News Image
a year ago - CASI Pharmaceuticals, Inc.

CASI PHARMACEUTICALS' PARTNER JUVENTAS ANNOUNCES NEW DRUG APPLICATION FOR CNCT19 ACCEPTED BY CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATION

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics...

News Image
a year ago - BusinessInsider

CASI PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2022 FINANCIAL RESULTS

ROCKVILLE, Md. and BEIJIN, Nov. 14, 2022 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on de...

News Image
a year ago - CASI Pharmaceuticals, Inc.

CASI PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2022 FINANCIAL RESULTS

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics...

News Image
2 years ago - CASI Pharmaceuticals, Inc.

CASI PHARMACEUTICALS ANNOUNCES EXIT OF JUVENTAS INVESTMENT TO STRENGTHEN BALANCE SHEET

/PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics...